Chinese biotech start-up GenoImmune has secured RMB120 million (US$17.87 million) in a series A round of financing led by GF Xinde Investment Management Co., a private equity affiliate of GF Securities, said GenoImmune in a statement released on Wednesday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?